Dyslipidemia in Type 2 Diabetes Mellitus

Overview

Journal Nat Clin Pract Endocrinol Metab

Specialty Endocrinology

Date 2009 Feb 21

PMID 19229235

Citations 399

Authors

Arshag D Mooradian

Affiliations

Soon will be listed here.

Abstract

Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. The characteristic features of diabetic dyslipidemia are a high plasma triglyceride concentration, low HDL cholesterol concentration and increased concentration of small dense LDL-cholesterol particles. The lipid changes associated with diabetes mellitus are attributed to increased free fatty acid flux secondary to insulin resistance. The availability of multiple lipid-lowering drugs and supplements provides new opportunities for patients to achieve target lipid levels. However, the variety of therapeutic options poses a challenge in the prioritization of drug therapy. The prevalence of hypercholesterolemia is not increased in patients with diabetes mellitus, but mortality from coronary heart disease increases exponentially as a function of serum cholesterol levels, and lowering of cholesterol with statins reduces diabetic patients' relative cardiovascular risk. Although drug therapy for dyslipidemia must be individualized, most people with diabetes mellitus are candidates for statin therapy, and often need treatment with multiple agents to achieve therapeutic goals.

Citing Articles

Altered leptin signaling and attenuated cardiac vagal activity in rats with type 2 diabetes.

Evans A, Tu H, Li Y, Shabaltiy B, Whitney L, Carpenter K Front Physiol. 2025; 16:1547901.

PMID: 40078371 PMC: 11897569. DOI: 10.3389/fphys.2025.1547901.

Association Between Different Thyroid-Stimulating Hormone Levels and Macrovascular Complications in Subclinical Hypothyroidism Patients With Type 2 Diabetes Mellitus.

Mahmud N, Jagdewsing D, Ji X, Harine I, Adjibou B, Fahmy N Cureus. 2025; 17(2):e79186.

PMID: 39967822 PMC: 11832303. DOI: 10.7759/cureus.79186.

The atherogenic index of plasma is associated with an increased risk of diabetes in non-obese adults: a cohort study.

Cao J, Su Z, Yang J, Zhang B, Jiang R, Lu W Front Endocrinol (Lausanne). 2025; 15:1477419.

PMID: 39902163 PMC: 11788137. DOI: 10.3389/fendo.2024.1477419.

Achillea millefolium capsule improved liver enzymes and lipid profile compared to placebo in patients with type 2 diabetes: a double-blind randomized clinical trial.

Daneshvar-Ghahfarokhi S, Ahmadinia H, Sadeghi T, Basirat E, Mohammadi-Shahrokhi V BMC Nutr. 2025; 11(1):21.

PMID: 39856724 PMC: 11761196. DOI: 10.1186/s40795-025-01005-5.

Probiotics: A Potential Strategy for Preventing and Managing Cardiovascular Disease.

Lopez-Yerena A, de Santisteban Villaplana V, Badimon L, Vilahur G, Padro T Nutrients. 2025; 17(1.

PMID: 39796486 PMC: 11722674. DOI: 10.3390/nu17010052.

References

Alam S, Stolinski M, Pentecost C, Boroujerdi M, Jones R, Sonksen P . The effect of a six-month exercise program on very low-density lipoprotein apolipoprotein B secretion in type 2 diabetes. J Clin Endocrinol Metab. 2004; 89(2):688-94. DOI: 10.1210/jc.2003-031036. View

McQueen M, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J . Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008; 372(9634):224-33. DOI: 10.1016/S0140-6736(08)61076-4. View

Beers A, Haas M, Wong N, Mooradian A . Inhibition of apolipoprotein AI gene expression by tumor necrosis factor alpha: roles for MEK/ERK and JNK signaling. Biochemistry. 2006; 45(7):2408-13. DOI: 10.1021/bi0518040. View

Williams P . The relationships of vigorous exercise, alcohol, and adiposity to low and high high-density lipoprotein-cholesterol levels. Metabolism. 2004; 53(6):700-9. DOI: 10.1016/j.metabol.2004.01.004. View

Dullaart R, de Vries R, Scheek L, Borggreve S, van Gent T, Dallinga-Thie G . Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest. 2004; 64(3):205-15. DOI: 10.1080/00365510410005721. View

Krauss R . Dietary and genetic probes of atherogenic dyslipidemia. Arterioscler Thromb Vasc Biol. 2005; 25(11):2265-72. DOI: 10.1161/01.ATV.0000186365.73973.f0. View

Moon Y, Kashyap M . Pharmacologic treatment of type 2 diabetic dyslipidemia. Pharmacotherapy. 2004; 24(12):1692-713. DOI: 10.1592/phco.24.17.1692.52340. View

Ballantyne C, Davidson M, McKenney J, Keller L, Bajorunas D, Karas R . Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008; 101(10):1428-36. DOI: 10.1016/j.amjcard.2008.02.092. View

Harris W, Ginsberg H, Arunakul N, Shachter N, Windsor S, Adams M . Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1998; 4(5-6):385-91. View

10.

. U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care. 1997; 20(11):1683-7. DOI: 10.2337/diacare.20.11.1683. View

11.

Frayn K . Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc. 2001; 60(3):375-80. DOI: 10.1079/pns200195. View

12.

Mensink R, Zock P, Kester A, Katan M . Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003; 77(5):1146-55. DOI: 10.1093/ajcn/77.5.1146. View

13.

Gu K, Cowie C, Harris M . Diabetes and decline in heart disease mortality in US adults. JAMA. 1999; 281(14):1291-7. DOI: 10.1001/jama.281.14.1291. View

14.

Kearney P, Blackwell L, Collins R, Keech A, Simes J, Peto R . Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371(9607):117-25. DOI: 10.1016/S0140-6736(08)60104-X. View

15.

Haffner S . Dyslipidemia management in adults with diabetes. Diabetes Care. 2003; 27 Suppl 1:S68-71. DOI: 10.2337/diacare.27.2007.s68. View

16.

Karas R, Kashyap M, Knopp R, Keller L, Bajorunas D, Davidson M . Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs. 2008; 8(2):69-81. DOI: 10.2165/00129784-200808020-00001. View

17.

Howard B, Roman M, Devereux R, Fleg J, Galloway J, Henderson J . Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA. 2008; 299(14):1678-89. PMC: 4243925. DOI: 10.1001/jama.299.14.1678. View

18.

Almdal T, Scharling H, Skov Jensen J, Vestergaard H . The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004; 164(13):1422-6. DOI: 10.1001/archinte.164.13.1422. View

19.

Kastelein J, Akdim F, Stroes E, Zwinderman A, Bots M, Stalenhoef A . Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358(14):1431-43. DOI: 10.1056/NEJMoa0800742. View

20.

Wilund K, Ferrell R, Phares D, Goldberg A, Hagberg J . Changes in high-density lipoprotein-cholesterol subfractions with exercise training may be dependent on cholesteryl ester transfer protein (CETP) genotype. Metabolism. 2002; 51(6):774-8. DOI: 10.1053/meta.2002.32730. View